Abstract Introduction Targeting Kirsten Rat Sarcoma (KRAS) has been deemed impossible
for long time, but new drugs have recently demonstrated promising results. Evidence on the …

BACKGROUND: KRAS gene mutations are well known as a key driver of advanced non–
small cell lung cancer (NSCLC). The impact of KRAS-mutant subtypes on the survival …

9596 Background: KRAS mutations are identified in approximately 30% of NSCLC. There
are no FDA approved targeted therapies for patients with KRAS-mutant non-small cell lung …

Simple Summary Non-small cell lung cancer (NSCLC) with Kirsten Rat Sarcoma Viral
Oncogene Homolog (KRAS) mutation comprises a specific subgroup of patients who are …

e19324 Background: KRAS G12C mutations are present in 15% of non-small cell lung
cancer (NSCLC) and have recently been shown to confer sensitivity to KRAS (G12C) …

Purpose: KRAS mutations are identified in approximately 30% of patients with non–small
cell lung cancer (NSCLC). Novel direct inhibitors of KRAS G12C have shown activity in early …

Introduction: Mutations in the RAS family of proto-oncogenes are frequently found in
NSCLC, with KRAS being the most prevalent mutated isoform. Of KRAS mutations, the most …

Despite the high prevalence of Kirsten rat sarcoma (KRAS) mutations in non-small cell lung
cancer (NSCLC), for a long time it has been defined as an 'undruggable target', with …

KRAS mutations represent one of the most prevalent oncogenic driver mutations in non-
small cell lung cancer (NSCLC). For many years we have unsuccessfully addressed KRAS …

Abstract Introduction The KRAS p. G12C mutation, prevalent in non–small-cell lung cancer
(NSCLC), has only recently become a viable target. Here we present results of the largest …